Study On The Clinical Pharmacist's Role In The Implementation Of Bronchial Asthma Clinical Pathway Which Based On PDCA Circulation

Objective:To investigate the role and working mode of clinical pharmacist in the implementation of clinical pathway of bronchial asthmaMethods:By the method of prospective case-control study,the 98 cases of respiratory patients from Pingxiang Hospital in July 2014 to June 2015, who met the inclusion criteria in clinical pathways of bronchial asthma,were assigned to the control group and the observation group. The observation groups entered into clinical pathway where clinical pharmacist participated, while the control groups entered into traditional clinical pathway with no help of clinical pharmacist.PDCA circulation theory was applied to manage the implementation of clinical pharmacist pathway.Two cycles were involved.The main indicators were hospitalization costs,drug treatment costs,the average hospitalization days,the adverse drug reactions(ADR),medication adherence and patient satisfication.Results:1.The research resuts of the control group and the observation groupA total of 134 patients with bronchial asthma were involved in the study,36(26.9%) of whom dropped out,46 of whom were assigned to the control group while 52 to the observation group.No significant differece in baseline clinical characteristics of patients was found between the two group patients.No significant differece in hospitalization costs and the average hospitalization days was found between the two groups. When compared with the conrol group, the drug treatment costs in the observation group were lower while the incidence of drug adverse reaction was higher. Significant differeces in medication adherence and patient satisfication were found between the two groups.2.The research resuts of 2 PDCA circulation in the observation groupThere were 28 patients involved in the first cycle while 24 in the second cycle.No significant differece in baseline clinical characteristics of patients was found between the patients.No significant differece in hospitalization costs ? the average hospitalization days ?the incidence of ADR and patient satisfication was found between the two PDCA groups. Significant differeces in medication adherence and the drug treatment costs were found between the two PDCA groups.3.The improvement of clinical pharmacist pathwayThere are 3 versiongs of “the clinical pharmacist's pathway table of bronchial asthma” after the improvement.Conclusions:Clinical pharmacists participate in the implementation of clinical pathway of bronchial asthma by providing theoretical evidence for the reasonable use of the drug?checking the doctor's advice?supervising patient adherence?monitoring adverse drug reactions ? drug monitoring ? medical education and the pharmaceutical ward round.These works are very important in improving the process of monitoring ADR ?reducing the drug treatment charge?improving the medication adherence and patient satisfication ? emdodying the value of clinical pharmacists. Standards for clinical pharmacists to participate in the woring mode of clinical pathway implementaion are set based on our sutdy.